Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis

BACKGROUND: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We evaluate baseline characteristics as predictors of sustained response and remission in patients with ulcerative colitis receiving tofacitinib maintenance therapy. METHODS: Patients with clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J, Armuzzi, Alessandro, Liguori, Giuseppina, Irving, Peter M, Sharara, Ala I, Mundayat, Rajiv, Lawendy, Nervin, Woolcott, John C, Danese, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434448/
https://www.ncbi.nlm.nih.gov/pubmed/34958359
http://dx.doi.org/10.1093/ibd/izab278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434448/
https://www.ncbi.nlm.nih.gov/pubmed/34958359
http://dx.doi.org/10.1093/ibd/izab278

Ejemplares similares